Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AEZS-108 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| AEZS-108 | DRUG | intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles |
Inclusion Criteria: * LHRH receptor positive tumor status: positive receptor status determined by immunohistochemistry from primary tumor * Histologically confirmed epithelial ovarian cancer (Stratum A) * Advanced (FIGO III or IV) or recurrent disease * Progression during treatment with a platinum-...
Top 20 of 59 competitors
AEZS-108 is an investigational small molecule being studied for the treatment of endometrial cancer and ovarian cancer. It is a targeted therapy that has been evaluated in clinical trials for these gynecological tumors. The drug is still in clinical development and is not approved by the FDA.
AEZS-108 targets LHRH receptors, which are found on certain gynecological tumors. By binding to these receptors, the drug is designed to deliver its anticancer effect specifically to cancer cells that express LHRH receptors. This targeted approach is being studied in patients with LHRH receptor positive tumors.
AEZS-108 is being developed by COSCIENS Biopharma Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with gynecological cancers. COSCIENS Biopharma Inc. is publicly traded under the ticker symbol CSCI.
AEZS-108 has completed a Phase 2 clinical trial and a Phase 3 clinical trial. The Phase 2 trial evaluated the drug in women with LHRH receptor positive gynecological tumors, while the Phase 3 trial studied it as a second-line therapy for endometrial cancer. The drug is investigational and not yet approved.
AEZS-108 has been studied in two completed clinical trials. The first, NCT00569257, was a Phase 2 trial in women with LHRH receptor positive ovarian and endometrial cancer. The second, NCT01767155, was a Phase 3 trial of zoptarelin doxorubicin (AEZS-108) as second-line therapy for endometrial cancer, enrolling 511 patients.
Yes, AEZS-108 is also known as zoptarelin doxorubicin. The Phase 3 clinical trial for endometrial cancer used the name zoptarelin doxorubicin (AEZS-108) to refer to the same drug. Both names refer to the same investigational compound being developed by COSCIENS Biopharma Inc.